SCHEMBL1184701

SCHEMBL1184701

O=C1CCC(=O)N(c2ccccc2)c2cc(Cl)ccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.56
MEN1 O00255 3/20 0.56
OPRK1 P41145 1/20 0.53
PDE4D Q08499 1/20 0.53
HPGD P15428 3/20 0.41
CASP6 P55212 1/20 0.40
RAF1 P04049 1/20 0.39
MAPK3 P27361 1/20 0.39
MAP3K8 P41279 1/20 0.39
MAP2K1 Q02750 1/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 3/20 0.38
ALOX15 P16050 2/20 0.38
HSD17B10 Q99714 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PTH1R Q03431 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1184633 0.77 MEN1 (0.61) KMT2AMEN1HTTALDH1A1L3MBTL1
SCHEMBL1184496 0.75 SRD5A1 (0.52) KMT2AOPRK1PDE4D
SCHEMBL11436899 0.74 OPRK1 (0.61) KMT2AMEN1OPRK1PDE4DHPGD
SCHEMBL11431631 0.74 OPRK1 (0.65) KMT2AMEN1OPRK1PDE4DHPGD
Lofendazam SCHEMBL1003371 0.74 OPRK1 (0.51) KMT2AMEN1OPRK1PDE4DHPGD
SCHEMBL10398760 0.74 OPRK1 (0.65) KMT2AMEN1OPRK1PDE4DHPGD
SCHEMBL9627368 0.73 OPRK1 (0.53) KMT2AMEN1OPRK1PDE4DHPGD
SCHEMBL11433565 0.71 OPRK1 (0.51) KMT2AMEN1OPRK1PDE4DHPGD
SCHEMBL11428325 0.71 OPRK1 (0.57) KMT2AMEN1OPRK1PDE4DHPGD
SCHEMBL16110543 0.71 OPRK1 (0.65) KMT2AMEN1OPRK1PDE4DHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799684-B1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARM INC (US) 2014-12-03 EP disclosed
US-20120178739-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-07-12 US disclosed
US-7935694-B2 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-05-03 US disclosed
US-20110039820-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 US disclosed
US-20090105213-A1 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-23 US disclosed
US-7459448-B2 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20060100194-A1 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100194-A1 Lactam compounds useful as protein kinase inhibitors PRKCI, PIK3CA, AKT1 KMT2A 2007/4885MEN1 1532/4885OPRK1 1535/4885
US-20120178739-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS PRKCI, PIK3CA, AKT1 KMT2A 2007/4885MEN1 1532/4885OPRK1 1535/4885
US-20090105213-A1 Lactam compounds useful as protein kinase inhibitors PRKCI, PIK3CA, AKT1 KMT2A 2007/4885MEN1 1532/4885OPRK1 1535/4885
US-20110039820-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS PRKCI, PIK3CA, AKT1 KMT2A 2007/4885MEN1 1532/4885OPRK1 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.